Key Highlights
- Dr. Stephen Hahn, former FDA Commissioner, joins as a Board member, contributing expertise in oncology and regulatory strategy.
- Dr. Jayson Dallas, biotech leader and CEO of Rivus Pharmaceuticals, brings extensive commercialization and operational experience.
- Strengthening leadership aligns with advancing Faeth’s AI-driven MetabOS platform and clinical oncology programs.
Source: Business Wire
Notable Quotes
- “Faeth’s approach of leveraging metabolic research in combination with AI has opened up metabolism as a new pillar in the treatment of cancer.” — Dr. Stephen Hahn, Former FDA Commissioner and Former Chief Medical Executive at MD Anderson Cancer Center
- “Faeth’s innovative approach to targeting cancer metabolism has the potential to transform treatment paradigms and unlock new drugs for development.” — Dr. Jayson Dallas, CEO at Rivus Pharmaceuticals
- “Their combined expertise will be invaluable as we accelerate our clinical programs and develop our MetabOS platform.” — Anand Parikh, CEO at Faeth Therapeutics
SoHC's Take
Faeth Therapeutics continues to position itself as a trailblazer in metabolic oncology with these strategic board appointments. Dr. Hahn’s unparalleled oncology and regulatory experience paired with Dr. Dallas’s commercialization expertise mark a significant milestone in Faeth’s journey to redefine cancer treatment. Their leadership is expected to drive innovation and bring transformative therapies closer to cancer patients worldwide.
